Developing evidence of the risks and benefits of PSA screening in black men to inform national guidelines and personalized decision-making
Active Grant Awarded
- Award ID
- R01CA315460
- Recipient
-
Veterans Medical Research Foundation Of San Diego UEI E4SPG9ZLLE76
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $460,134
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 7% complete
- Place of performance
- San Diego, CA 92161, USA
Award details come from USAspending.gov.
About this award
The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded Veterans Medical Research Foundation of San Diego $460,134 on July 20, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394), for Grant R01CA315460. The grant funds a secondary analysis of Veterans Health Administration (VHA) data to determine the benefits and harms of prostate-specific antigen (PSA) screening in Black men, a population that comprised only 4.4% of participants in landmark PSA trials. The ultimate completion date is June 30, 2031, and the place of performance is San Diego, CA 92161.
The recipient will analyze longitudinal data from more than 5 million veterans, including over 900,000 Black men, across 130 VHA facilities from 2005 to 2024. The work uses VHA's Informatics and Computing Infrastructure (VINCI), which integrates the Corporate Data Warehouse (60+ data domains) with additional datasets. The methodology combines individual-level marginal structural models addressing time-dependent confounding, facility-level analyses exploiting natural practice variation, and population-level microsimulation modeling. Natural language processing will automatically detect metastatic outcomes.
Description
- Abstract
- Background: prostate cancer affects american men of all backgrounds, but its burden falls unevenly. Black men face 64% higher incidence (188.7 VS. 114.9 per 100,000) and more than double the mortality (36.9 VS. 18.4 per 100,000) compared to non-hispanic white men. Despite this elevated risk, PSA screening guidelines lack evidence-based recommendations for black men because black men comprised only 4.4% of participants in landmark trials (e.g., plco). Major guideline organizations (uspstf, nccn, ACS) explicitly call for research to address this critical evidence GAP. Objective: conduct comprehensive secondary analysis of veterans health administration (VHA) data to determine PSA screening benefits and harms specifically in black men, addressing the largest evidence GAP in PSA screening for high-risk populations. Methods: analyze longitudinal data from 5+ million veterans of varied backgrounds (including 900,000+ black men) across 130 VHA facilities, 2005-2024; the largest cohort of black men with detailed PSA screening data ever assembled. Use triangulated methodology: (1) individual-level marginal structural models addressing time-dependent confounding, (2) facility-level analyses exploiting natural practice variation, and (3) population-level microsimulation modeling. Analysis leverages VHA's informatics and computing infrastructure (VINCI), integrating the corporate data warehouse (60+ data domains) with additional datasets, enabling comprehensive multi-level analysis impossible with traditional single-dataset approaches. Innovation: pioneers marginal structural model application to PSA screening research, leverages unprecedented VINCI dataset integration, and employs multi-level triangulation maximizing analytical rigor. Advanced natural language processing automatically detects metastatic outcomes (97.9% specificity) while facility practice variation provides natural experiments for causal inference. Enhanced microsimulation incorporates real-world VHA data rather than survey-based estimates. Impact: results will inform evidence-based race-specific PSA screening recommendations for black men, the group at the highest risk. Team includes national guideline panel members (nccn, ACS) positioned for rapid policy translation. The resulting framework improves screening for the highest-burden group, while advancing real-world methods applicable to all men. Expected outcomes: deliver race-specific estimates of PSA screening benefits and harms, enabling tailored recommendations that optimize the benefit-harm ratio for black men. This project delivers solution-oriented research using integrated real-world data, advancing NIH priorities in real-world data science and training the next generation of physician-scientists.
Quick answers
Who received award R01CA315460?
R01CA315460 was awarded to Veterans Medical Research Foundation Of San Diego by National Cancer Institute (National Institutes of Health) on July 20, 2026.
How much is award R01CA315460 worth?
$460,134 has been obligated on R01CA315460.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award